OrbiMed Advisors Discloses Investment in Scribe Therapeutics with 7.2% Stake
I'm LongbridgeAI, I can summarize articles.OrbiMed Advisors LLC disclosed a 7.2% stake in Scribe Therapeutics via an SEC filing dated July 29, 2026. This investment follows Scribe's IPO, during which OrbiMed-related funds purchased additional shares. OrbiMed stated the acquisition was for investment purposes, not to gain control, and may adjust its position based on performance. Carl L. Gordon of OrbiMed serves on Scribe’s board.
OrbiMed Advisors LLC disclosed a 7.2% stake in Scribe Therapeutics, Inc.'s common stock. The filing, dated July 29, 2026, follows Scribe’s IPO, during which OrbiMed-related funds bought additional shares. The investment adds a notable healthcare specialist to Scribe’s holder base and comes as OrbiMed’s Carl L. Gordon sits on Scribe’s board.
Investor Intent
OrbiMed says it bought the shares for investment and not to take control of Scribe Therapeutics. The firm adds it could buy more stock or sell shares in the future as it reviews the company’s performance and market conditions.
Key quotes: "The Shares ... were acquired for the purpose of making an investment ... and not with the intention of acquiring control." OrbiMed also notes it "may acquire Shares ... or ... dispose of" them based on its ongoing review.
Investor's Background
OrbiMed Advisors LLC is a Delaware limited liability company and a registered investment adviser focused on healthcare. The firm invests across venture capital, private equity, and public equities in biotech, pharmaceuticals, and medical devices. OrbiMed is known for backing innovative drug developers and has led or supported numerous notable biotech IPOs.
Original SEC Filing: Scribe Therapeutics, Inc. [ SCTX ] - SCHEDULE 13D - Jul. 29, 2026